Brief: Spyre Announces Potential Best-In-Class Spy003 (Anti-Il-23) Part A Induction Results From Skyline Trial, Completing Proof-Of-Concept For All Three Components Of Its Ibd Combinations
08/09/2026 13:11
BRIEF-Spyre Announces Potential Best-In-Class Spy003 (Anti-Il-23) Part A Induction Results From Skyline Trial, Completing Proof-Of-Concept For All Three Components Of Its Ibd Combinations Sept 8 (Reuters) - Spyre Therapeutics Inc SYRE.O:
SPYRE ANNOUNCES POTENTIAL BEST-IN-CLASS SPY003 (ANTI-IL-23) PART A INDUCTION RESULTS FROM SKYLINE TRIAL, COMPLETING PROOF-OF-CONCEPT FOR ALL THREE COMPONENTS OF ITS IBD COMBINATIONS
SPYRE THERAPEUTICS - SPY003 MEETS PRIMARY ENDPOINT WITH 10.0-POINT RHI REDUCTION AT WEEK 12
SPYRE THERAPEUTICS - SPY003 ACHIEVES 20% CLINICAL REMISSION AND 30% ENDOSCOPIC IMPROVEMENT AT WEEK 12
SPYRE THERAPEUTICS - SKYLINE PART B ENROLLING; TOPLINE INDUCTION DATA EXPECTED IN 2027
SPYRE THERAPEUTICS - SPY003 WELL TOLERATED WITH SAFETY PROFILE CONSISTENT WITH IL-23 CLASS
Source text: ID:nGNX8FBBfC
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock